# A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

> **NCT02790840** · PHASE1 · COMPLETED · sponsor: **Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Omeprazole
- **DRUG:** Omeprazole
- **DRUG:** Gefapixant
- **DRUG:** Gefapixant

## Key facts

- **NCT ID:** NCT02790840
- **Lead sponsor:** Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-16
- **Primary completion:** 2016-06-15
- **Final completion:** 2016-06-21
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02790840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02790840, "A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02790840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*